Loading patent…
OwnerLars Henrik Hoieinventor
Estimating the term…
A composition comprising (a) soy protein, (b) a phytoestrogen compound, and (c) dietary fibres is provided. The soy protein (a) is present in an amount of at least 45 weight percent of the total protein content of the composition, said total protein content providing at least 15 percent of the total energy content of the composition. The phytoestrogen compound (b) is preferably a naturally occurring isoflavone and is present in an amount of more than 0.10 weight percent of the soy protein, and the dietary fibres (c) are preferably soybean fibres and are present in an amount of more than 6 weight percent of the total weight of the nutritional composition on a dry basis. The composition is useful for treating various diseases. Alternatively, the phytoestrogen is more than 0.55 weight percent of the soy protein and the dietary fibers are more than 4 weight percent of the total weight.
1 (amended). A composition comprising
A composition according to claim 1, wherein the soy protein source is isolated soy protein and the amount of isolated soy protein is at least 50 weight percent of the total protein content.
A composition according to claim 1, wherein the soy protein source is soy protein concentrate or soy flour and the amount of soy protein is at least 50 weight percent of the total protein content.
A composition according to claim 1, wherein the dietary fibers are soybean fibers.
A composition according to claim 1 wherein the phytoestrogen compound is present in an amount of at least about 0.20 weight percent of the soy protein content of the composition.
A composition according to claim 1 wherein at least one of the phytoestrogen compounds is an isoflavone.
A composition according to claim 1 wherein the dietary fibers are present in an amount of at least 7 weight percent of the composition.
A composition according to claim 1 wherein the weight ratio of soy protein of dietary fibers is at least about 1.0.
A composition according to claim 1, further comprising one or more statins, bile acid resins, fibrates, nicotinic acid derivatives, oat products, rye products or fish oil concentrates with a high content of ω-3-fatty acids, or any combination thereof.
A composition according to claim 1 further comprising an additional protein source and/or an additional carbohydrate source and/or an additional fat source.
A composition according to claim 1 in the form of a micronutrient.
A composition according to claim 1, further comprising a functional food ingredient comprising a sterol.
A composition according to claim 1, suitable for use as a food or as an ingredient of a food.
A composition according to claim 1 which is classified by the U.S. Food and Drug Administration as a food for special dietary use.
A method of preventing, treating, prophylactically treating and/or alleviating by therapy a cardiovascular disease in a human or animal body, said method comprising administration to said human or animal body of a composition according to claim 1 in an amount effective in lowering serum levels of total cholesterol and/or LDL-cholesterol and/or triglycerides and/or homocystein and/or increasing the serum HGL/LDL-cholesterol ratio and/or serum HDL-cholesterol levels and/or reducing the influx of cholesterol and/or triglycerides into the arterial wall and/or reducing the amount of oxidized LDL-cholesterol present in the arterial wall and/or preventing, reducing or eliminating fatty streak formation and/or preventing, reducing or eliminating fibrous plaque formation and/or preventing, reducing or eliminating complicated lesion formation and/or reducing or eliminating the risk of a subject contracting angina pectoris and/or reducing or eliminating the risk of subject contracting a myocardial infarction and/or alleviating the clinical condition of patients contracting a myocardial infection.
Method of preventing and/or treating by therapy type 2 diabetes in a human or animal body, said method comprising administration to said human or animal body of a composition according to claim 1 in an amount effective in lowering serum levels of glucose and/or total cholesterol and/or LDL-cholesterol and/or triglycerides and/or homocystein and/or reducing the influx of cholesterol and/or triglycerides into the arterial wall and/or reducing the amount of oxidized LDL-cholesterol present in the arterial wall and/or improving glucose tolerance and/or increasing insulin sensitivity and/or alleviating impaired glucose tolerance and/or improving insulin secretion and/or reducing or eliminating fatty streak formation and/or preventing, reducing or eliminating fibrous plaque formation and/or preventing, reducing or eliminating complicated lesion formation and/or preventing, reducing or eliminating complicated lesion formation and/or preventing, reducing or eliminating the risk of a diabetic subject contracting angina pectoris and/or preventing, reducing or eliminating the risk of a diabetic subject contracting a myocardial infarction and/or preventing, treating, prophylactically treating, alleviating and/or eliminating hypertension and/or hyperglycemia and/or hyperinsulinemia and/or hypercholesterolemia and/or hypertriglyceridemia and/or arteriosclerosis and/or atherosclerosis and/or arteriolosclerosis in a diabetic subject.
Method of preventing and/or treating by therapy the metabolic syndrome in a human or animal body, said method comprising administration to said human or animal body of a composition according to claim 1 in an amount effective in lowering serum levels of glucose and/or total cholesterol and/or LDL-cholesterol and/or triglycerides and/or homocystein and/or reducing the influx of cholesterol and/or triglycerides into the arterial wall and/or reducing the amount of oxidized LDL-cholesterol present in the arterial wall and/or improving glucose tolerance and/or increasing insulin sensitivity and/or alleviating impaired glucose tolerance and/or improving insulin secretion and/or reducing or eliminating fatty streak formation and/or preventing, reducing or eliminating fibrous plaque formation and/or preventing, reducing or eliminating complicated lesion formation and/or preventing, reducing or eliminating the risk of a subject contracting angina pectoris and/or preventing, reducing or eliminating the risk of a subject contracting a myocardial infarction.
A composition according to claim 1 wherein the phytoestrogen compounds are present in a total amount of at least about 0.18 weight percent of the soy protein content of the composition.
A composition according to claim 1 wherein the phytoestrogen compounds are present in a total amount of at least about 0.55 weight percent of the soy protein content of the composition.
A composition comprising
Dependencies are inferred from the claim text.